The GTSE1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the HAP1 cell line, designed to disrupt the GTSE1 gene and facilitate functional studies of its role in cell cycle regulation and p53 signaling. This product consists of a heterogeneous pool of cells harboring gene-disrupting edits, enabling robust loss-of-function analysis without clonal isolation. The polyclonal format is ideal for pooled screens and bulk assays where population-level knockout phenotypes are examined.
HAP1 is an adherent, near-haploid cell line originating from the KBM-7 chronic myeloid leukemia line. Its haploid genome simplifies genetic manipulation, as disruption of a single allele typically results in a null phenotype for autosomal genes. This characteristic has made HAP1 a valuable model for genetic screens, drug target validation, and functional genomics, particularly in cancer research.
GTSE1 is a p53-inducible protein that functions at the intersection of the DNA damage response and mitotic progression. It is transcriptionally activated by TP53 and, in turn, binds to p53 to inhibit its transactivation function, thereby blocking p53-mediated apoptosis and cell cycle arrest. During mitosis, GTSE1 associates with microtubules and is phosphorylated by CDK1 and PLK1, promoting spindle organization and G2/M transition. Key interacting factors include TP53, ??-tubulin, CDK1, and PLK1. Aberrant GTSE1 expression is linked to chemoresistance and tumorigenesis in multiple cancers.
In the HAP1 haploid background, GTSE1 knockout provides a clean single-allele disruption model to dissect its dual roles in p53 regulation and mitotic machinery. This system enables direct measurement of GTSE1-dependent changes in p53 activity, mitotic spindle integrity, and cell cycle distribution. The polyclonal knockout pool is particularly suited for population-averaged readouts in drug sensitivity and proliferation assays, minimizing clonal artifacts.
Typical applications include studying p53 signaling via western blotting for p53 and p21, RT-qPCR for p53 targets, and immunofluorescence for mitotic spindle markers. Cell cycle analysis by flow cytometry, apoptosis assays under genotoxic stress, and co-immunoprecipitation of GTSE1 with TP53 or CDK1 are also common. This knockout tool is valuable for drug target validation and synthetic lethality screens in cancer models. For further information, contact Ascent Research.
